Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ross Stuart Berkowitz, M.D.

Co-Author

This page shows the publications co-authored by Ross Berkowitz and Christopher Crum.
Connection Strength

1.686
  1. Human papillomaviruses. Applications, caveats and prevention. J Reprod Med. 2002 Jul; 47(7):519-28; discussion 528-9.
    View in: PubMed
    Score: 0.253
  2. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. J Pathol. 2018 11; 246(3):344-351.
    View in: PubMed
    Score: 0.195
  3. Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA. Mod Pathol. 2017 03; 30(3):448-458.
    View in: PubMed
    Score: 0.171
  4. Relationship of margin status and radiation dose to recurrence in post-operative vulvar carcinoma. Gynecol Oncol. 2013 Sep; 130(3):545-9.
    View in: PubMed
    Score: 0.135
  5. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007 Feb; 31(2):161-9.
    View in: PubMed
    Score: 0.087
  6. Influence of margin status and radiation on recurrence after radical hysterectomy in Stage IB cervical cancer. Int J Radiat Oncol Biol Phys. 2006 Aug 01; 65(5):1501-7.
    View in: PubMed
    Score: 0.083
  7. Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers (Basel). 2021 Jun 28; 13(13).
    View in: PubMed
    Score: 0.059
  8. Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions. Cancers (Basel). 2021 May 03; 13(9).
    View in: PubMed
    Score: 0.058
  9. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res. 2021 01 01; 81(1):158-173.
    View in: PubMed
    Score: 0.056
  10. MicroRNA-200 family governs ovarian inclusion cyst formation and mode of ovarian cancer spread. Oncogene. 2020 05; 39(20):4045-4060.
    View in: PubMed
    Score: 0.054
  11. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol. 2019 May; 38(3):230-240.
    View in: PubMed
    Score: 0.051
  12. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 11; 8(11):1404-1421.
    View in: PubMed
    Score: 0.049
  13. Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. Elife. 2017 10 31; 6.
    View in: PubMed
    Score: 0.046
  14. Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome. Int J Gynecol Pathol. 2017 Mar; 36(2):115-127.
    View in: PubMed
    Score: 0.044
  15. Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. Mod Pathol. 2016 08; 29(8):893-903.
    View in: PubMed
    Score: 0.041
  16. Molecular changes in endometriosis-associated ovarian clear cell carcinoma. Eur J Cancer. 2015 Sep; 51(13):1831-42.
    View in: PubMed
    Score: 0.039
  17. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. Int J Cancer. 2015 Aug 15; 137(4):776-83.
    View in: PubMed
    Score: 0.038
  18. Analysis of HPV-positive and -negative vulvar carcinomas for alterations in c-myc, Ha-, Ki-, and N-ras genes. Gynecol Oncol. 1994 Apr; 53(1):78-83.
    View in: PubMed
    Score: 0.036
  19. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol. 2014 Feb; 132(2):280-6.
    View in: PubMed
    Score: 0.035
  20. Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomes. PLoS One. 2013; 8(11):e80314.
    View in: PubMed
    Score: 0.035
  21. BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2. Neoplasia. 2013 Jun; 15(6):600-8.
    View in: PubMed
    Score: 0.034
  22. Utility of chromosomal chromogenic in situ hybridization as an alternative to flow cytometry and cytogenetics in the diagnosis of early partial hydatidiform moles: a validation study. J Reprod Med. 2010 Jul-Aug; 55(7-8):275-8.
    View in: PubMed
    Score: 0.028
  23. The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol. 2010 Jan; 220(1):17-23.
    View in: PubMed
    Score: 0.027
  24. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007 Sep 01; 25(25):3985-90.
    View in: PubMed
    Score: 0.023
  25. Twin pregnancies with complete hydatidiform mole and coexisting fetus: use of fluorescent in situ hybridization to evaluate placental X- and Y-chromosomal content. Hum Pathol. 1995 Nov; 26(11):1175-80.
    View in: PubMed
    Score: 0.010
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.